Latest & greatest articles for chronic kidney disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on chronic kidney disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on chronic kidney disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for chronic kidney disease

241. A prediction model for the risk of incident chronic kidney disease

A prediction model for the risk of incident chronic kidney disease 20800153 2010 08 30 2010 09 13 2015 11 19 1555-7162 123 9 2010 Sep The American journal of medicine Am. J. Med. A prediction model for the risk of incident chronic kidney disease. 836-846.e2 10.1016/j.amjmed.2010.05.010 Chronic kidney disease is a health burden for the general population. We designed a cohort study to construct prediction models for chronic kidney disease in the Chinese population. A total of 5168 participants (...) were followed up during a median of 2.2 (interquartile range, 1.5-2.9) years, and 190 individuals (3.7%) developed chronic kidney disease, defined by a glomerular filtration rate of less than 60 mL/min/1.73 m(2). We developed a point system to estimate chronic kidney disease risk at 4 years using the following variables: age (8 points), body mass index (2 points), diastolic blood pressure (2 points), and history of type 2 diabetes (1 point) and stroke (4 points) for the clinical model

EvidenceUpdates2010

242. Chronic kidney disease and risk of major cardiovascular disease and non-vascular mortality: prospective population based cohort study.

Chronic kidney disease and risk of major cardiovascular disease and non-vascular mortality: prospective population based cohort study. OBJECTIVE: To quantify associations of chronic kidney disease stages with major cardiovascular disease and non-vascular mortality in the general adult population. DESIGN: Prospective population based cohort study. SETTING: Reykjavik, Iceland. PARTICIPANTS: 16 958 people aged 33-81 years without manifest vascular disease and with available information on stage (...) of chronic kidney disease (defined by both estimated glomerular filtration rate and urinary protein) at study entry. MAIN OUTCOME MEASURES: Hazard ratios for time to major coronary heart disease outcomes and mortality. RESULTS: 1210 (7%) of participants had chronic kidney disease at entry. During a median follow-up of 24 years, 4010 coronary heart disease outcomes, 559 deaths from stroke, and 3875 deaths from non-vascular causes were recorded. Compared with the reference group (estimated

BMJ2010 Full Text: Link to full Text with Trip Pro

243. Guidelines for the prevention and management of Mycobacterium tuberculosis infection and disease in adult patients with chronic kidney disease

Guidelines for the prevention and management of Mycobacterium tuberculosis infection and disease in adult patients with chronic kidney disease 20522863 2010 06 04 2010 11 04 2016 11 22 1468-3296 65 6 2010 Jun Thorax Thorax Guidelines for the prevention and management of Mycobacterium tuberculosis infection and disease in adult patients with chronic kidney disease. 557-70 10.1136/thx.2009.133173 Guidelines have been compiled by the Joint Tuberculosis Committee of the British Thoracic Society (...) for the prevention and management of Mycobacterium tuberculosis infection and disease in patients with all grades of renal impairment. British Thoracic Society Standards of Care Committee and Joint Tuberculosis Committee Milburn Heather H Ashman Neil N Davies Peter P Doffman Sarah S Drobniewski Francis F Khoo Saye S Ormerod Peter P Ostermann Marlies M Snelson Catherine C eng G0901364 Medical Research Council United Kingdom Journal Article Practice Guideline Review England Thorax 0417353 0040-6376 0

EvidenceUpdates2010

244. Predicting potential survival benefit of renal transplantation in patients with chronic kidney disease

Predicting potential survival benefit of renal transplantation in patients with chronic kidney disease 20351122 2010 04 20 2010 09 16 2014 12 04 1488-2329 182 7 2010 Apr 20 CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne CMAJ Predicting potential survival benefit of renal transplantation in patients with chronic kidney disease. 666-72 10.1503/cmaj.091661 To facilitate decision-making about treatment options for patients with end-stage renal disease (...) considering kidney transplantation, we sought to develop an index for clinical prediction of risk for death. We derived and validated a multivariable survival model predicting time to death in 169,393 patients with end-stage renal disease who were eligible for transplantation. We modified the model into a simple point-system index. Deaths occurred in 23.5% of the cohort. Twelve variables independently predicted death: age, race, cause of kidney failure, body mass index, comorbid disease, smoking

EvidenceUpdates2010 Full Text: Link to full Text with Trip Pro

245. Association between major depressive episodes in patients with chronic kidney disease and initiation of dialysis, hospitalization, or death.

Association between major depressive episodes in patients with chronic kidney disease and initiation of dialysis, hospitalization, or death. CONTEXT: Patients with chronic kidney disease (CKD) experience increased rates of hospitalization and death. Depressive disorders are associated with morbidity and mortality. Whether depression contributes to poor outcomes in patients with CKD not receiving dialysis is unknown. OBJECTIVE: To determine whether the presence of a current major depressive (...) ). CONCLUSION: The presence of an MDE was associated with an increased risk of poor outcomes in CKD patients who were not receiving dialysis, independent of comorbidities and kidney disease severity.

JAMA2010 Full Text: Link to full Text with Trip Pro

246. Evaluation of a nurse-led disease management programme for chronic kidney disease: a randomized controlled trial

Evaluation of a nurse-led disease management programme for chronic kidney disease: a randomized controlled trial 19651405 2010 02 17 2010 05 12 2010 09 24 1873-491X 47 3 2010 Mar International journal of nursing studies Int J Nurs Stud Evaluation of a nurse-led disease management programme for chronic kidney disease: a randomized controlled trial. 268-78 10.1016/j.ijnurstu.2009.07.001 Patients with end stage renal failure require dialysis and strict adherence to treatment plans to sustain life (...) . However, non-adherence is a common and serious problem among patients with chronic kidney disease. There is a scarcity of studies in examining the effects of disease management programmes on patients with chronic kidney disease. This paper examines whether the study group receiving the disease management programme have better improvement than the control group, comparing outcomes at baseline (O1), at 7 weeks at the completion of the programme (O2) and at 13 weeks (O3). This is a randomized controlled

EvidenceUpdates2010

247. Early recognition and prevention of chronic kidney disease.

Early recognition and prevention of chronic kidney disease. Chronic kidney disease is a common disorder and its prevalence is increasing worldwide. Early diagnosis on the basis of presence of proteinuria or reduced estimated glomerular filtration rate could permit early intervention to reduce the risks of cardiovascular events, kidney failure, and death that are associated with chronic kidney disease. In developed countries, screening for the disorder is most efficient when targeted at high (...) -risk groups including elderly people and those with concomitant illness (such as diabetes, hypertension, or cardiovascular disease) or a family history of chronic kidney disease, although the role of screening in developing countries is not yet clear. Effective strategies are available to slow the progression of chronic kidney disease and reduce cardiovascular risk. Treatment of high blood pressure is recommended for all individuals with, or at risk of, chronic kidney disease. Use of angiotensin

Lancet2010

248. Cost effectiveness of paricalcitol versus a non-selective vitamin D receptor activator for secondary hyperparathyroidism in the UK: a chronic kidney disease Markov model

Cost effectiveness of paricalcitol versus a non-selective vitamin D receptor activator for secondary hyperparathyroidism in the UK: a chronic kidney disease Markov model Cost effectiveness of paricalcitol versus a non-selective vitamin D receptor activator for secondary hyperparathyroidism in the UK: a chronic kidney disease Markov model Cost effectiveness of paricalcitol versus a non-selective vitamin D receptor activator for secondary hyperparathyroidism in the UK: a chronic kidney disease (...) for secondary hyperparathyroidism in chronic kidney disease (CKD), compared with the usual care of alfacalcidol, in the UK setting. Interventions Alfacalcidol was a non-selective vitamin D receptor activator that had been used to treat secondary hyperparathyroidism, but a substantial number of patients with hypercalcaemia or hyperphosphataemia could not be treated. This was compared with paricalcitol, which could benefit these patients. Location/setting UK/tertiary care. Methods Analytical approach

NHS Economic Evaluation Database.2010

249. Randomised controlled trial: A nurse-led disease management programme for chronic kidney disease improves outcomes such as adherence to diet and continuous ambulatory peritoneal dialysis

Randomised controlled trial: A nurse-led disease management programme for chronic kidney disease improves outcomes such as adherence to diet and continuous ambulatory peritoneal dialysis A nurse-led disease management programme for chronic kidney disease improves outcomes such as adherence to diet and continuous ambulatory peritoneal dialysis | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in via your Society Log (...) in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here A nurse-led disease management programme for chronic kidney disease improves outcomes such as adherence to diet

Evidence-Based Nursing (Requires free registration)2010

250. Quality-improvement strategies for the management of hypertension in chronic kidney disease in primary care: a systematic review

Quality-improvement strategies for the management of hypertension in chronic kidney disease in primary care: a systematic review Quality-improvement strategies for the management of hypertension in chronic kidney disease in primary care: a systematic review Quality-improvement strategies for the management of hypertension in chronic kidney disease in primary care: a systematic review Gallagher H, de Lusignan S, Harris K, Cates C CRD summary This review concluded that quality improvement (...) interventions could be effective in reducing blood pressure in high-risk populations with chronic kidney disease or diabetes. The applicability of the findings to lower-risk populations was uncertain. Limitations in the evidence base and review methods suggest that the conclusions should be interpreted cautiously. Authors' objectives To assess the effectiveness of quality improvement interventions to reduce systolic blood pressure in people with chronic kidney disease in primary care. Searching

DARE.2010

251. Cost-effectiveness of screening and optimal management for diabetes, hypertension, and chronic kidney disease: a modeled analysis

Cost-effectiveness of screening and optimal management for diabetes, hypertension, and chronic kidney disease: a modeled analysis Cost-effectiveness of screening and optimal management for diabetes, hypertension, and chronic kidney disease: a modeled analysis Cost-effectiveness of screening and optimal management for diabetes, hypertension, and chronic kidney disease: a modeled analysis Howard K, White S, Salkeld G, McDonald S, Craig JC, Chadban S, Cass A Record Status This is a critical (...) and optimal management for diabetes, hypertension, and chronic kidney disease: a modeled analysis. Value in Health 2010; 13(2): 196-208 PubMedID DOI Original Paper URL Indexing Status Subject indexing assigned by NLM MeSH Adult; Aged; Australia; Cost-Benefit Analysis; Diabetes Mellitus, Type 2 /complications /diagnosis /economics /therapy; Humans; Hypertension /complications /diagnosis /economics /therapy; Kidney Failure, Chronic /diagnosis /economics /etiology /therapy; Markov Chains; Mass Screening

NHS Economic Evaluation Database.2010

252. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease

Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Tonelli M, Garg AX, Pellegrini F, Ravani P, Jardine M, Perkovic V, Graziano G, McGee R, Nicolucci A, Tognoni G, Strippoli GF CRD summary This review assessed the effects (...) of erythropoiesis-stimulating agents on anaemia in patients with chronic kidney disease and concluded that higher haemoglobin target levels increased risks of stroke, hypertension and vascular access thrombosis. Risk of death, serious cardiovascular events and end-stage renal disease may also be increased, but further research was needed. The authors' recommendations for further research seem appropriate. Authors' objectives To assess the effects of erythropoiesis-stimulating agents on anaemia in patients

DARE.2010

254. Effectiveness of medical compared to multidisciplinary models of care for adult persons with pre-dialysis chronic kidney disease: a systematic review

Effectiveness of medical compared to multidisciplinary models of care for adult persons with pre-dialysis chronic kidney disease: a systematic review Effectiveness of medical compared to multidisciplinary models of care for adult persons with pre-dialysis chronic kidney disease: a systematic review Effectiveness of medical compared to multidisciplinary models of care for adult persons with pre-dialysis chronic kidney disease: a systematic review Strand H, Parker D CRD summary The authors (...) concluded that multidisciplinary care was effective in delaying the progression of chronic kidney disease in adults who were in the pre-dialysis phase of this condition. The reliability of the authors' conclusions is uncertain due to the small number and unclear quality of the included studies and potential for language and publication biases. Authors' objectives To compare the effectiveness of multidisciplinary care with traditional medical care on the progression of chronic kidney disease in adult pre

DARE.2010

255. Intensive blood-pressure control in hypertensive chronic kidney disease.

Intensive blood-pressure control in hypertensive chronic kidney disease. 20818902 2010 09 07 2010 09 16 2016 11 22 1533-4406 363 10 2010 Sep 02 The New England journal of medicine N. Engl. J. Med. Intensive blood-pressure control in hypertensive chronic kidney disease. 918-29 10.1056/NEJMoa0910975 In observational studies, the relationship between blood pressure and end-stage renal disease (ESRD) is direct and progressive. The burden of hypertension-related chronic kidney disease and ESRD is (...) especially high among black patients. Yet few trials have tested whether intensive blood-pressure control retards the progression of chronic kidney disease among black patients. We randomly assigned 1094 black patients with hypertensive chronic kidney disease to receive either intensive or standard blood-pressure control. After completing the trial phase, patients were invited to enroll in a cohort phase in which the blood-pressure target was less than 130/80 mm Hg. The primary clinical outcome

NEJM2010 Full Text: Link to full Text with Trip Pro

256. Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease?Mineral and Bone Disorder (CKD-MBD) Guidelines: a European Renal Best Practice (ERBP) commentary statement

Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease?Mineral and Bone Disorder (CKD-MBD) Guidelines: a European Renal Best Practice (ERBP) commentary statement Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) Guidelines: a European Renal Best Practice (ERBP) commentary statement | Nephrology Dialysis Transplantation | Oxford Academic We use cookies to enhance your experience (...) on our website. By continuing to use our website, you are agreeing to our use of cookies. You can change your cookie settings at any time. Search Account Menu Menu Navbar Search Filter Mobile Microsite Search Term Close search filter search input Article Navigation Close mobile search navigation Article navigation December 2010 Article Contents Article Navigation Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) Guidelines

European Renal Best Practice2010

258. Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy

Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy 19786678 2009 09 29 2009 10 15 2016 10 19 1538-3679 169 17 2009 Sep 28 Archives of internal medicine Arch. Intern. Med. Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy. 1587-94 10.1001/archinternmed.2009.284 The incidence and factors associated with hyperkalemia in patients with chronic kidney disease (CKD) treated (...) with angiotensin converting enzyme inhibitors (ACEIs) and other antihypertensive drugs was investigated using the African American Study of Kidney Disease and Hypertension (AASK) database. A total of 1094 nondiabetic adults with hypertensive CKD (glomerular filtration rate [GFR], 20-65 mL/min/1.73 m(2)) were followed for 3.0 to 6.4 years in the AASK trial. Participants were randomly assigned to ACEI, beta-blocker (BB), or dihydropyridine calcium channel blocker (CCB). The outcome variables for this analysis

EvidenceUpdates2009

259. Defining incident chronic kidney disease in the research setting: The ARIC Study

Defining incident chronic kidney disease in the research setting: The ARIC Study 19535543 2009 07 29 2009 08 11 2017 02 20 1476-6256 170 4 2009 Aug 15 American journal of epidemiology Am. J. Epidemiol. Defining incident chronic kidney disease in the research setting: The ARIC Study. 414-24 10.1093/aje/kwp151 Deaths of participants and losses to follow-up pose challenges for defining outcomes in epidemiologic studies. The authors compared several definitions of incident chronic kidney disease (...) Male Middle Aged Prospective Studies Renal Insufficiency, Chronic diagnosis epidemiology ethnology mortality Risk Factors Terminology as Topic United States epidemiology PMC2727177 2009 6 19 9 0 2009 6 19 9 0 2009 8 12 9 0 ppublish 19535543 kwp151 10.1093/aje/kwp151 PMC2727177

EvidenceUpdates2009 Full Text: Link to full Text with Trip Pro

260. The role of specialists in managing the health of populations with chronic illness: the example of chronic kidney disease.

The role of specialists in managing the health of populations with chronic illness: the example of chronic kidney disease. PROBLEM: Specialty care has been used to manage individual patients at the discretion of generalists but not to drive improvements at the population level. DESIGN: Observational longitudinal study. SETTING: Kaiser Permanente Hawaii, with more than 10,000 members with documented chronic kidney disease. KEY MEASURES FOR IMPROVEMENT: Rate of late referrals to nephrology care (...) nephrology consultations is an effective strategy for increasing the quality of medical management of patients with chronic kidney disease in the primary care setting and improving the cost effective use of nephrology services. This approach may be broadly applicable to other specialty areas.

BMJ2009